



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/583,731

02/19/2008

Bakulesh Mafatlal Khamar

21059/0206949-us0

8375

7278

7590

12/23/2008

DARBY & DARBY P.C.

P.O. BOX 770

Church Street Station

New York, NY 10008-0770

EXAMINER

SWARTZ, RODNEY P

ART UNIT

PAPER NUMBER

1645

MAIL DATE

DELIVERY MODE

12/23/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/583,731	Applicant(s) KHAMAR ET AL.	
	Examiner Rodney P. Swartz, Ph.D.	Art Unit 1645	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 25 September 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-26 and 29 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-26,29 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. Applicants' Response to Office Action, received 25 September 2008, is acknowledged.

Claims 1, 3-18, 22-26 and 29 have been amended.

2. Claims 1-26 and 29 are pending and under consideration.

Rejections/Objections Withdrawn

3. The objection to claims 1, 2, 4-7, 10-16, and 29 because occurrences of "Mycobacterium w" should be in italics, is withdrawn in light of the amendment of the claims.

4. The objection to claim 7 because "ingredient" should be "gradient" is withdrawn in light of the amendment of the claim.

5. The objection to claim 17 because in line 5, "antigen" should be "antigens" is withdrawn in light of the amendment of the claim.

6. The objection to claim 25 because in line 3, "morlatity" should be "mortality" is withdrawn in light of the amendment of the claim.

7. The rejection of claim 12 under 35 U.S.C. 112, second paragraph, as being indefinite for not ending with a period, is withdrawn in light of the amendment of the claim.

The rejection of claim 13 under 35 U.S.C. 112, second paragraph, as being indefinite for the modifier "preferably" is withdrawn in light of the amendment of the claim.

8. The rejection of claim 14 under 35 U.S.C. 112, second paragraph, as being indefinite for the term "resembling", is withdrawn in light of the amendment of the claim.

9. The rejection of claim 15 under 35 U.S.C. 112, second paragraph, as being indefinite for the trademark/trade name TWEEN 80, is withdrawn in light of the amendment of the claim.

The rejection of claim 17 under 35 U.S.C. 112, second paragraph, as being indefinite for an antigen encoded "in" nucleic acids, is withdrawn in light of the amendment of the claim.

Rejections/Objections Maintained

10. The objection to claims 3, 8 and 9 because occurrences of "*Mycobacterium w*" should be in italics, is maintained because not all occurrences have been corrected.

11. The rejection of claims 1-17, 22-26 and 29 under 35 U.S.C. 102(b) as being anticipated by Khamar et al (WO 03/049667) is maintained.

Applicants argue that Khamar et al do not teach a composition with an antigen therein. Applicants argue that the examiner has inadvertently rejected claim 16 and 17 even the claims specifically recite an antigen.

The examiner has considered applicants arguments, but does not find them persuasive. Firstly, claim 16 does not designate any particular antigen and claim 17 recites that the antigen may be one or more peptides without restricting the source of the peptides. Claim 1 is a composition comprising *Mycobacterium w* or constituents thereof, an antigen, and a carrier. Since *Mycobacterium w* comprises peptides, the *Mycobacterium w* may serve both as the antigen and the adjuvant. The claims do not restrict the source of the antigen.

12. The rejection of claims 1-17, 22-26 and 29 under 35 U.S.C. 102(b) as being anticipated by Khamar et al (WO 03/075825) is maintained.

Applicants argue that Khamar et al do not teach a composition with an antigen therein. Applicants argue that the examiner has inadvertently rejected claim 16 and 17 even the claims specifically recite an antigen.

The examiner has considered applicants arguments, but does not find them persuasive. Firstly, claim 16 does not designate any particular antigen and claim 17 recites that the antigen may be one or more peptides without restricting the source of the peptides. Claim 1 is a composition comprising *Mycobacterium w* or constituents thereof, an antigen, and a carrier.

Art Unit: 1645

Since *Mycobacterium w* comprises peptides, the *Mycobacterium w* may serve both as the antigen and the adjuvant. The claims do not restrict the source of the antigen.

13. The rejection of claims 19-21 under 35 U.S.C. 112, second paragraph, as being indefinite for dependence from rejected claims, is maintained.

New Rejection Necessitated by Amendment

Claim Rejections - 35 USC § 112

14. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

15. Claim 18 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 18 is now dependent from a rejected claim.

Conclusion

16. No claims are allowed.

17. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a).

Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a)

Art Unit: 1645

will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rodney P. Swartz, Ph.D., Art Unit 1645, whose telephone number is (571) 272-0865. The examiner can normally be reached on Monday through Wednesday from 9:00 AM to 7:30 PM EST. Thursday is the examiner's work at home day.

If attempts to reach the Examiner by telephone are unsuccessful, please contact the Examiner's Supervisor, Robert B. Mondesi (571)272-0956.

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Rodney P. Swartz, Ph.D./

Primary Examiner, Art Unit 1645

December 18, 2008